SCHEMBL4125517

SCHEMBL4125517

CCCCCCCCCCCC(=O)N1CCCC(C(=O)N(CC)CC)C1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 4/20 0.64
▸ MEN1 O00255 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ L3MBTL1 Q9Y468 2/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ POLB P06746 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ HPGD P15428 1/20 0.51
▸ GNAI3 P08754 6/20 0.48
▸ GNAO1 P09471 6/20 0.48
▸ GNAI1 P63096 6/20 0.48
▸ ITGB3 P05106 1/20 0.46
▸ ITGA2B P08514 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.45
▸ NAMPT P43490 1/20 0.45
▸ LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4144152 1.00 BCHE (0.64) BCHEMEN1KMT2AL3MBTL1TDP1
SCHEMBL4139217 1.00 BCHE (0.64) BCHEMEN1KMT2AL3MBTL1TDP1
SCHEMBL4139168 1.00 BCHE (0.64) BCHEMEN1KMT2AL3MBTL1TDP1
SCHEMBL13772518 0.92 BCHE (0.56) BCHEMEN1KMT2AL3MBTL1TDP1
SCHEMBL13772503 0.91 BCHE (0.57) BCHEMEN1KMT2AL3MBTL1TDP1
SCHEMBL3737600 0.90 BCHE (0.59) BCHEMEN1KMT2AL3MBTL1TDP1
SCHEMBL13772501 0.89 BCHE (0.58) BCHEMEN1KMT2AL3MBTL1TDP1
SCHEMBL13772509 0.88 BCHE (0.50) BCHEMEN1KMT2AL3MBTL1TDP1
SCHEMBL13772512 0.87 BCHE (0.49) BCHEMEN1KMT2AL3MBTL1TDP1
SCHEMBL13772505 0.86 BCHE (0.60) BCHEMEN1KMT2APOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2100602-A1 Method and compositions suitable for treatment of wounds QuoNova Europe GmbH (DE) 2009-09-16 — — EP disclosed
US-20090192192-A1 INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA TOUCH BIONICS LIMITED (GB) 2009-07-30 — — US disclosed
US-20090192192-A1 INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA TOUCH BIONICS LIMITED (GB) 2009-07-30 — — US disclosed
US-20090192192-A1 INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA TOUCH BIONICS LIMITED (GB) 2009-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192192-A1 INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA PGLS, TFPI, Q6ZSR9 BCHE 2865/4885MEN1 4659/4885KMT2A 3636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback